Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar-Apr;5(2):105-13.
doi: 10.1016/j.jacl.2011.02.001.

Clinical implications of discordance between low-density lipoprotein cholesterol and particle number

Affiliations

Clinical implications of discordance between low-density lipoprotein cholesterol and particle number

James D Otvos et al. J Clin Lipidol. 2011 Mar-Apr.

Abstract

Background: The amount of cholesterol per low-density lipoprotein (LDL) particle is variable and related in part to particle size, with smaller particles carrying less cholesterol. This variability causes concentrations of LDL cholesterol (LDL-C) and LDL particles (LDL-P) to be discordant in many individuals.

Methods: LDL-P measured by nuclear magnetic resonance spectroscopy, calculated LDL-C, and carotid intima-media thickness (IMT) were assessed at baseline in the Multi-Ethnic Study of Atherosclerosis, a community-based cohort of 6814 persons free of clinical cardiovascular disease (CVD) at entry and followed for CVD events (n = 319 during 5.5-year follow-up). Discordance, defined as values of LDL-P and LDL-C differing by ≥ 12 percentile units to give equal-sized concordant and discordant subgroups, was related to CVD events and to carotid IMT in models predicting outcomes for a 1 SD difference in LDL-C or LDL-P, adjusted for age, gender, and race.

Results: LDL-C and LDL-P were associated with incident CVD overall: hazard ratios (HR 1.20, 95% CI [CI] 1.08-1.34; and 1.32, 95% CI 1.19-1.47, respectively, but for those with discordant levels, only LDL-P was associated with incident CVD (HR 1.45, 95% CI 1.19-1.78; LDL-C HR 1.07, 95% CI 0.88-1.30). IMT also tracked with LDL-P rather than LDL-C, ie, adjusted mean IMT of 958, 932, and 917 microm in the LDL-P > LDL-C discordant, concordant, and LDL-P < LDL-C discordant subgroups, respectively, with the difference persisting after adjustment for LDL-C (P = .002) but not LDL-P (P = .60).

Conclusions: For individuals with discordant LDL-C and LDL-P levels, the LDL-attributable atherosclerotic risk is better indicated by LDL-P.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relations between LDL-C and LDL-P among 5598 MESA participants. (A) Relation of LDL-C and LDL-P concentrations. (B) Relation of LDL-C and LDL-P levels given in percentile units. The dashed lines bracket concordant LDL-C and LDL-P values defined as those within ±12 percentile units.
Figure 2
Figure 2
Cumulative incidence of cardiovascular events in subgroups with concordant or discordant levels of LDL-C and LDL-P, from proportional hazards models adjusted for age, gender, and race. The 3 subgroups are the same as in Table 1; mean levels of LDL-P and LDL-C are adjusted for age, gender, and race.
Figure 3
Figure 3
Cumulative incidence of cardiovascular events in subgroups with low LDL-C and/or low LDL-P, from proportional hazards models adjusted for age and gender. Low LDL-C and LDL-P values were defined as < 100 mg/dL and <1060 nmol/L, respectively (<30th percentile).
Figure 4
Figure 4
Carotid IMT in μm by tertile of LDL-C (top) or LDL-P (bottom) in 3 subgroups with concordant or discordant LDL levels. Least squares mean IMT and 95% confidence intervals are from multiple linear regression models adjusted for age, gender, race, systolic blood pressure, hypertension treatment, smoking, body mass index, and diabetes status. Subgroups analyzed: LDL-P > LDL-C discordant; n=1126 (formula image), concordant; n=2246 (formula image), LDL-P < LDL-C discordant; n=1127 (formula image).

Comment in

References

    1. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Amer J Cardiol. 2002;90(suppl):22i–29i. - PubMed
    1. Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, Wilson PWF, D’Agostino RB. LDL particle number and risk for future cardiovascular disease in the Framingham Offspring Study – implications for LDL management. J Clin Lipidol. 2007;1:583–92. - PMC - PubMed
    1. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832–44. - PubMed
    1. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witzum JL. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512–24. - PubMed
    1. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847–70. - PubMed

Publication types